abstract |
The present invention relates to an antibody for specifically binding to a Lysyl-tRNA synthetase N-terminal domain exposed to an extracellular membrane and, more specifically, to an antibody or a fragment thereof that specifically binds to a Lysyl-tRNA synthetase (KRS) N-terminal domain exposed to an extracellular membrane having a specific complementarity determining region (CDR) sequence described in the present specification, and use of a composition comprising the antibody or the fragment thereof as an active ingredient for preventing, treating, or diagnosing cancer, cancer metastasis, or immune cell migration-related diseases. The method of the present invention may be utilized to prepare an antibody with a higher affinity at a KRS N-terminus than existing antibodies. |